


About Albemarle Asset Management

Albemarle Asset Management was founded in London in 2003. The company provides both individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our services cover global financial markets and our expertise enables us to offer diverse set of investment instruments and strategies.

Performance

	YTD	1M	3YR	5YR	Inception
Fund		1.67%			1.52%
Benchmark		1.91%			23.62%
	Best Mth	Worst Mth	CAGR	Vol	Sharpe R.
Fund	4.95%	-3.62%			
Benchmark	9.83%	-2.42%			

Chart Performance



Fund Objective

Target Global Equity is a sub-fund of Apsley Fund ICAV an open-ended investment company with variable capital incorporated in Ireland. The investment objective of the sub-fund is to achieve long-term capital growth through a predominantly equity strategy with moderate fluctuations.

Fund Information

Company	Apsley Fund ICAV
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	APSGBEI ID Equity
ISIN	IE00BKTPJD17
Inception	15/04/2020
	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	1.50% p.a.
Performance Fees	15% of the amount by which the NAV exceeds the High Watermark level
NAV	Daily
Cut-Off	T-1 before 1pm Irish Time
Stlmt date for sub.	T+2 Irish Business Days
Stlmt date for red.	T+2 Irish Business Days
Domicile	Ireland
Auditors	Grant Thornton
Depositary	Northern Trust Fiduciary Services (Ireland) Ltd
Category	UCITS V


Ratings and Awards

Important Information

The information contained within this document is for the use of Institutional and Professional Investors only

* Data source: Bloomberg


Sector Breakdown Net Exposure (%)




Top Holdings

BKO 0 09/16/22	25.10%
FRTR 0 02/25/22	5.36%
JP Morgan Chase & Co.	3.09%
Coca Cola Co.	2.99%
Apple Inc.	2.10%
Total	38.64%

Asset Allocation Exposure



Country Breakdown Net Exposure



Commentary

The Fund posted a positive performance of 1.67% during the December, while its invested portion returned 2.29% and kept its gross equity exposure at 96% MoM. On the Fund level, exposure to Financials and IT sectors led the performance, whereas Health Care has dragged. The main positive contributors to the Fund's performance were long S&P500 E-mini futures, ASML Holding and Apple; whilst the Fund suffered from its exposure to Sanofi and Nokia. The main trades executed were futures on MSCI World December 2020 (sell to close), S&P E-mini March 2021 (long), and Nasdaq 100 E-mini March 2021 (long).

Disclaimer

This information is being communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is only directed and may only be distributed to persons who are Professional Clients or Eligible Counterparties and is not, under any circumstances, intended for distribution to the general public. With investment, your capital is at risk and the value of an investment and the income from it can go up as well as down, it may be affected by exchange rate variations and you may not get back the amount invested. Past performance is not necessarily a guide to future performance. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read in conjunction with the relevant fund documentation which may include the fund's prospectus, simplified prospectus or supplement documentation and if you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.